Shareholders Clear 500M Share Increase, Reject Amended Articles
VRAX sits 18% above its 52-week low of $2.5.
Summary
At the August 21 adjourned meeting, shareholders approved a 250x increase in authorized shares to 500 million, while rejecting the amended articles proposal. The vote clears the path for heavy dilution as the company seeks capital to address its going concern status.
Key Events · Corporate Governance and Compliance · VRAX
-
Share Capital Increase Approved
At the August 21, 2026 adjourned meeting, shareholders approved increasing authorized shares from 2,000,000 to 500,000,000 — a 250x increase.
-
Amended Articles Rejected
Proposal 2 to adopt the fifth amended and restated memorandum and articles of association was not approved, leaving the company's constitutional documents out of sync with the new authorized share capital.
-
Voting Results
Proposal 1 passed with 61,471 for, 54,414 against, and 4,342 abstaining. Proposal 2 failed with 66,754 for, 53,203 against, and 270 abstaining.
-
Quorum Challenges
The initial August 14 meeting lacked quorum with only 6.33% of shares present. The adjourned meeting proceeded with 8.94% present under the Articles' fallback quorum rule.
Analysis · VRAX · Life Sciences
The approval of a 250x increase in authorized shares to 500 million clears the way for significant future dilution. Notably, the rejection of the amended articles proposal means the share capital increase takes effect without the corresponding governance changes, creating a mismatch between authorized capital and the company's constitutional documents. With only 1.34 million shares outstanding and a going concern warning from the July 20-F, this approval gives management substantial headroom to issue shares for survival financing.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRAX was trading at $2.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $2.50 to $21.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.